Donor-Derived Cell-Free DNA Levels for Liver Transplant Rejection Diagnosis

40 primary whole liver transplant recipients were enrolled in a prospective single-center diagnostic study. The research, authored by Zhigao Deng and last updated in May 2026, dynamically monitored donor-derived cell-free DNA levels from 14 days to 1 year post-transplant to diagnose and monitor acute rejection.

Use Cases

• Diagnosing acute liver transplant rejection based on donor-derived cell-free DNA percentage and copy number thresholds.
• Monitoring the efficacy of anti-rejection therapy by tracking changes in donor-derived cell-free DNA levels over time.
• Comparing the diagnostic performance of a novel biomarker against routine liver function tests using ROC curve analysis.
• Developing logistic regression models to predict acute rejection events in transplant recipients.

Strengths

• The study provides specific diagnostic cutoffs: dd-cfDNA% ≥10.39% (sensitivity 95%, specificity 90%) and dd-cfDNA ≥1928 copies/mL (sensitivity 70%, specificity 90%).
• Performance metrics are reported, including an AUC of 0.940 for dd-cfDNA% and 0.823 for dd-cfDNA copy number.
• Data collection was prospective and used pathological biopsy as the gold standard for comparison.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is from a single-center study with 40 participants, which may limit generalizability.

Provenance

Source

Zhigao Deng

Collection Method

Prospective single-center diagnostic study enrolling 40 liver transplant recipients.

Time Range

Data monitored from 14 days to 1 year post-transplant.

Freshness

Last updated 2026-05-11 04:26:22; freshness should be verified.